C-reactive protein (CRP) is a significant prognostic indicator in patients with advanced renal cell carcinoma (RCC) treated with sunitinib, according to Japanese researchers.
“Pretreatment CRP level could be a useful biomarker for response to sunitinib treatment,” the authors concluded in the International Journal of Urology (published online ahead of print).
Tetsuo Fujita, MD, and colleagues at Kitasato University School of Medicine, Sagamihara, Kanagawa, studied 41 patients with advanced clear-cell RCC treated with sunitinib. Of these, 11 (26.8%) showed a partial response to treatment and 10 (24.4%) had stable disease. Patients with normal CRP levels (30 mg/dL or less) had a significantly higher rate of partial response and stable disease (84.6% vs. 35.7%) and significantly longer progression-free survival (median 19 vs. 6 months) than patients with elevated CRP levels.
CRP is a non-specific inflammatory acute-phase protein and a representative marker of systemic inflammatory response.